MassHealth Ends GLP-1 Weight-Loss Coverage for 22,000, Citing $15 Million in Savings
Updated
Updated · The Boston Globe · Jul 2
MassHealth Ends GLP-1 Weight-Loss Coverage for 22,000, Citing $15 Million in Savings
1 articles · Updated · The Boston Globe · Jul 2
Summary
Friday’s cutoff ends MassHealth coverage of GLP-1 drugs prescribed solely for weight loss, affecting about 22,000 Medicaid patients in Massachusetts, including roughly 2,500 children.
MassHealth said the drugs’ cost had become unsustainable after federal Medicaid changes reduced state funding; the agency expects the policy to save about $15 million.
Coverage will continue for diabetes and some obesity-related conditions, but doctors said many younger patients without qualifying comorbidities now face stopping treatment, switching to cheaper drugs, or paying out of pocket.
Physicians warned many patients regain significant weight within months off GLP-1s, risking renewed hypertension, diabetes and mental-health strain, while making the drugs less accessible to low-income patients.
The move leaves Massachusetts joining most state Medicaid programs in limiting coverage even as Medicare has started a pilot expanding access to some GLP-1s.
Why is Medicare expanding obesity drug access while state Medicaid programs are cutting it?
What happens to 22,000 patients when their state cuts coverage for a life-changing drug?
Massachusetts Medicaid Cuts GLP-1 Coverage for Weight Loss by July 2026 Amid Budget Crisis and Federal Expansion
Overview
MassHealth will end coverage for GLP-1 and other anti-obesity medications prescribed solely for weight loss starting July 1, 2026, reversing a policy that began in January 2024. This major shift comes as Massachusetts faces rising healthcare costs and a growing budget gap, making the high spending on these medications a key target for savings. State agencies, including the Group Insurance Commission, are considering dropping coverage to pressure drug manufacturers to lower prices. This decision reflects a broader trend among states to limit Medicaid coverage for costly weight-loss drugs, prioritizing immediate fiscal stability over broader access to obesity treatments.